Changes in Hong Kong stocks | Collumbotai Biotech (06990) rose more than 3% to partially achieve positive results in phase 2 of the POLARIS-1 clinical trial and has initiated phase 3 clinical trials

The Zhitong Finance App learned that Colunbotai Biotech (06990) rose more than 3%. As of press release, it had risen 3.35% to HK$480.8, with a turnover of HK$253 million.

According to the news, recently, Colombotai Biotech announced that the company's partner Windward Bio AG (Windward Bio) has announced that SKB378/WIN378 (an all-human ultra-long-acting monoclonal antibody targeting thymic matrix lymphopoietin (TSLP)) achieved positive interim results in phase 2 of the POLARIS-1 clinical trial for the treatment of asthma. SKB378/WIN378 is a novel all-human ultra-long-lasting monoclonal antibody. It has a unique binding pattern and can effectively inhibit TSLP.

The phase 3 portion of Polaris-1 has been initiated by Windward Bio to determine the use of two dosage regimens with two doses per year to assess the effects of SKB378/WIN378 on the annual acute incidence rate of asthma and other key efficacy indicators in patients with severe asthma. Additionally, Windward Bio plans to launch the second phase 3 clinical study Polaris-2 in the first half of 2027. The data from the Phase 2 study of POLARIS-1 will be presented at an upcoming medical conference.